JNBA Financial Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

JNBA Financial Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100	Closed	–	–	744
2019 Q2	$0	Buy	+100	New	+$295	﹤0.01%	709

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JNBA Financial Advisors's ACHN Position: Q3 2019 in Review

JNBA Financial Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q3 2019, closing a stake of 100 shares.

JNBA Financial Advisors first reported a position in ACHN in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

JNBA Financial Advisors reported no remaining Achillion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
JNBA Financial Advisors sold 100 Achillion Pharmaceuticals shares in Q3 2019.
JNBA Financial Advisors first reported a position in Achillion Pharmaceuticals in Q2 2019 and held it in 1 quarter.
JNBA Financial Advisors's Achillion Pharmaceuticals position peaked at $0 in Q2 2019.
122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on JNBA Financial Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.